The purpose of this study is to evaluate the effects of concentrated growth factor (CGF) on pain after bilateral impacted third molar surgery and to determine its contribution to the healing process.

The main question it aims to answer is:

Is CGF effective on reducing the pain in impacted third molar surgery? Researchers compare the pain on the CGF-applied and CGF free sides after impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale. TThe postoperative outcomes including pain are clinically assessed at different-time intervals (1-7 days).

Inclusion Criteria:

• Patients with bilateral, symmetrical, bone-retained (vertical, mesioangular, horizontal) impacted wisdom teeth in the mandible, regardless of gender
• Patients without any systemic disease
• Patients who have been informed about the duration, purpose and requirements of the study and who have signed the informed consent form voluntarily.

Exclusion Criteria:

• Having a disease affecting general health that requires the application of prophylactic antimicrobial agents
• Having a systemic viral, fungal or bacterial infection
• Patients with acute or chronic maxillary sinusitis
• Suspected or diagnosed pregnancy and nursing mothers
• Patients with heart and vascular diseases
• Patients with liver disease, haematological disease and neoplastic disease
• Patients who have recently received anti-inflammatory therapy
• Patients with chronic medication use (antihistamines, NSAIDs, steroids and antidepressants)
• Patients predisposed to psychotic or psychopathic tendencies
• Patients with rheumatic diseases, blood diseases, diabetes mellitus
• Patients at cardiological risk of infective endocarditis
• Patients under antibiotic pressure